HCMT
PTGX icon

Highland Capital Management (Tennessee)’s Protagonist Therapeutics PTGX Stock Holding History

Highland Capital Management (Tennessee)’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,462
Closed -$215K – 452
2025
Q4 		$215K Buy
+2,462
New +$202K 0.01% 386

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Highland Capital Management (Tennessee)'s PTGX Position: Q1 2026 in Review

Highland Capital Management (Tennessee) sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 2,462 shares — an estimated $215K sold.

Highland Capital Management (Tennessee) first reported a position in PTGX in Q4 2025 and held it in 1 quarter. The position peaked at $215K in Q4 2025. 319 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Highland Capital Management (Tennessee) reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Highland Capital Management (Tennessee) sold 2,462 Protagonist Therapeutics shares in Q1 2026, an estimated $215K.
  • Highland Capital Management (Tennessee) first reported a position in Protagonist Therapeutics in Q4 2025 and held it in 1 quarter.
  • Highland Capital Management (Tennessee)'s Protagonist Therapeutics position peaked at $215K in Q4 2025.
  • 319 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Highland Capital Management (Tennessee)'s 13F filing for Q1 2026, filed 13 Apr 2026.